Ripertamab

Summary

Ripertamab (CHEMBL4594604) is a phase-3 clinical-stage antibody; indicated across 2 conditions including diffuse large b-cell lymphoma and neoplasm of mature b-cells.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody
• Indications: 2 conditions
• Clinical trials: 6

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4594604
Name	Ripertamab
Type	Antibody
Max phase	3

Also known as: Ripertamab, SCT-400, Sct400, SCT400, RIPERTAMAB

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
diffuse large B-cell lymphoma	3	MONDO:0018905	EFO:0000403
neoplasm of mature B-cells	2	MONDO:0004949	EFO:0000096

Clinical trials

Total trials: 6.

Phase distribution

Phase	Trials
PHASE3	2
Not specified	2
PHASE2	1
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06405100	PHASE3	NOT_YET_RECRUITING	Efficacy and Safety of Tacrolimus in Combination With Ripertamab in the Initial Treatment of Patients With MCD
NCT06858722	PHASE3	NOT_YET_RECRUITING	Ripertamab for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy
NCT07372807	PHASE1/PHASE2	NOT_YET_RECRUITING	Ripertamab for the Treatment of Myasthenia Gravis
NCT02456207	PHASE2	UNKNOWN	A Pharmacokinetic Study Comparing SCT400 And Rituximab in Patients With B-cell Non-Hodgkin’s Lymphoma
NCT06790888	Not specified	NOT_YET_RECRUITING	Ripertamab Plus Eltrombopag vs. Eltrombopag in ITP Patients Post-Steroid Failure
NCT07388810	Not specified	NOT_YET_RECRUITING	Study of Ripertamab in Children With Frequent Relapses or Steroid-Dependent Nephrotic Syndrome

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).